Ignite Creation Date:
2025-12-25 @ 3:11 AM
Ignite Modification Date:
2026-02-23 @ 9:22 PM
Study NCT ID:
NCT02169505
Status:
TERMINATED
Last Update Posted:
2019-11-27
First Post:
2014-06-11
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Brentuximab Vedotin in High-Risk CD30+ Lymphoma Post Allogeneic Stem Cell Transplantation (AlloSCT)
Sponsor:
M.D. Anderson Cancer Center
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2015-05-22
Start Date Type:
ACTUAL
Primary Completion Date:
2017-08-14
Primary Completion Date Type:
ACTUAL
Completion Date:
2017-08-14
Completion Date Type:
ACTUAL
First Submit Date:
2014-06-11
First Submit QC Date:
None
Study First Post Date:
2014-06-23
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2018-04-06
Results First Submit QC Date:
None
Results First Post Date:
2019-05-17
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2019-11-15
Last Update Post Date:
2019-11-27
Last Update Post Date Type:
ACTUAL